Please wait while the formulary information is being retrieved.
Drug overview for PROSTIN VR PEDIATRIC (alprostadil):
Generic name: ALPROSTADIL
Drug class: Alprostadil
Therapeutic class: Cardiovascular Therapy Agents
Alprostadil, the naturally occurring prostaglandin E1, is a vasodilating agent and a platelet-aggregation inhibitor.
No enhanced Uses information available for this drug.
Generic name: ALPROSTADIL
Drug class: Alprostadil
Therapeutic class: Cardiovascular Therapy Agents
Alprostadil, the naturally occurring prostaglandin E1, is a vasodilating agent and a platelet-aggregation inhibitor.
No enhanced Uses information available for this drug.
DRUG IMAGES
PROSTIN VR PEDI 500 MCG/ML AMP
The following indications for PROSTIN VR PEDIATRIC (alprostadil) have been approved by the FDA:
Indications:
Congenital heart defect requiring patency of ductus arteriosus
Professional Synonyms:
Congenital heart defect requiring pre-surgery patency of PDA
Ductal-dependent cardiac lesion
Indications:
Congenital heart defect requiring patency of ductus arteriosus
Professional Synonyms:
Congenital heart defect requiring pre-surgery patency of PDA
Ductal-dependent cardiac lesion
The following dosing information is available for PROSTIN VR PEDIATRIC (alprostadil):
Dosage of intracavernosal alprostadil must be individualized carefully according to the patient's erectile response. Initiation and titration of dosage should be undertaken in a medical setting, and the patient must remain in this setting during titration of each dose until complete detumescence occurs. If no response occurs with a given dose, upward titration should be attempted after about 1 hour; no more than 2 injections should be administered initially within a 24-hour period.
If a response is observed, at least 24 hours should elapse before administering the next dose. Dosage should be titrated slowly to the lowest possible effective level in order to avoid priapism.
For the treatment of neurogenic impotence secondary to spinal cord injury, the usual adult intracavernosal dose of alprostadil ranges from 1.25-60 mcg. Generally, therapy is started with the smaller dosage and increased until the optimum dose (as determined by maintenance of an erection that is satisfactory for intercourse but persists no longer than 1 hour) is attained.
For the treatment of pure neurogenic impotence (i.e., spinal cord injury), the manufacturers recommend an initial intracavernosal dose of 1.25 mcg of alprostadil administered in a medical setting. If no response is observed with the initial dose of alprostadil, the dose may be doubled to 2.5
mcg after about 1 hour; no more than 2 doses should be administered within a 24-hour period. If additional dosage titration is required, a dose of 5 mcg may be administered during the next 24 hours, followed by subsequent increases in 5-mcg increments, with each incremental increase separated by at least 24 hours, until optimum response is achieved. If the duration of the erection achieved exceeds 1 hour, the subsequent dose of alprostadil should be reduced.
For the treatment of vasculogenic erectile dysfunction, psychogenic erectile dysfunction, or erectile dysfunction of mixed etiology, the manufacturers recommend an initial intracavernosal test dose of alprostadil of 2.5 mcg. If a partial response is observed, the dose may be doubled to 5 mcg after about 1 hour.
If no response to the initial test dose is observed, then the second dose may be increased to 7.5 mcg after about 1 hour. No more than 2 doses should be administered within a 24-hour period.
If additional titration is required, dosage may be increased in increments of 5-10 mcg at intervals of at least 24 hours until optimum response is achieved.
In clinical trials, most patients with erectile dysfunction of various etiologies responded to initial intracavernosal alprostadil doses titrated to exceeding 5 but not exceeding 20 mcg, with the dose at the end of the titration phase averaging 17.8 mcg. Although doses ranging from 0.2-140
mcg have been reported, almost all patients who respond to alprostadil do so at doses of 60 mcg or less; therefore, doses exceeding 60-65 mcg generally are not recommended.
Dosage of intraurethral alprostadil should be individualized according to the patient's erectile response. Since symptomatic hypotension and syncope occurred in 3 and 0.4% of patients, respectively, using intraurethral alprostadil during the initial (dose-titrating) phase, initiation and titration of dosage should be undertaken in a medical setting to monitor the patients for manifestations of such effects.
Patients should inform their clinician if they have a history of syncope. It is recommended that therapy with intraurethral alprostadil be initiated with low doses (e.g., 125 or 250 mcg); dosage should be titrated (in separate visits) to the lowest possible effective level in order to avoid development of hypotension or syncope, which appear to be dose related. If no response occurs with these doses, subsequent doses may be increased in a stepwise manner to 500 or 1000 mcg, as needed.
In clinical studies, 6-10, 17-20, 20-30 or 27-56% of patients achieved adequate penile response (erections sufficient for intercourse) at intraurethral alprostadil doses during the dosage-titration phase (to establish home maintenance dosage) of 125-, 250-, 500-, or 1000 mcg, respectively.
Intracavernosal alprostadil self-injection therapy for erectile dysfunction should be initiated at the dose that was determined as optimal during titration in a medical setting (e.g., physician's office); however, the first self-administered dose should be delayed for at least 1 day after completion of supervised dose titration but also should be administered in a medical setting. The optimal maintenance dose should result in an erection that is maintained for no longer than 1 hour. Adjustments to the initial office-titrated dose often are required to maintain response in the home, but should be attempted only after consultation with a clinician (not independently by the patient), following the same initial titration guidelines.
The manufacturers recommend that patients self-administer intracavernosal alprostadil no more frequently than 3 times weekly with at least 1 day elapsing between each dose. Follow-up monitoring of patients should be performed every 3 months to determine safety (e.g., careful examination of the penis for fibrotic changes) and the possible need for additional dosage adjustment. Alprostadil therapy should be discontinued if penile angulation, cavernosal fibrosis, or Peyronie's disease develop.
The manufacturer of Caverject(R) states that efficacy of long-term alprostadil therapy for erectile dysfunction has been established for up to 6 months by an uncontrolled, self-injection study; at 6 months, the optimal dose averaged 20.7 mcg. Doses exceeding 60-65 mcg generally are not recommended.
Prolonged erection (persisting 4-6 hours) or priapism (erection persisting 6 hours or longer) occurred in 4 or 0.4% of patients, respectively, receiving intracavernosal alprostadil in clinical studies. However, priapism is a medical emergency that could result in penile tissue damage and permanent loss of potency if not treated immediately, and therefore, patients should be advised to report promptly to their physician or, if unavailable, to seek alternative immediate medical attention if an erection that persists longer than 4 hours or that is extremely painful occurs.
Management of priapism or prolonged erection should be according to established medical practice, and has included aspiration of cavernosal blood and/or intracavernosal injection of an alpha-adrenergic agonist (i.e., phenylephrine, epinephrine) or dopamine; priapism may be more likely during dose titration than during maintenance (home) therapy. Rarely, more radical therapy for priapism (e.g., cavernospongiosus or Winter's shunt) may be necessary, such as in patients with persistent priapism (e.g., for longer than 24 hours).
The most common adverse effect associated with intracavernosal alprostadil use is penile pain, which was reported at least once in 37% of patients in clinical studies of up to 18 months' duration. In most cases, such pain was described as mild to moderate in intensity, although 3% of patients discontinued therapy with the drug because of penile pain. Patients should be advised to report to their clinician penile pain that develops or intensifies during intracavernosal alprostadil therapy.
Patients also should be vigilant for the development of nodules or hard areas in the penis and be instructed to report any sign of infection (e.g., penile erythema, swelling, tenderness, or unusual curvature).
Penile fibrosis, including Peyronie's disease, developed in 3% of patients receiving intracavernosal alprostadil in clinical studies; in one self-injection study in which the drug was administered for up to 18 months, the incidence of fibrosis was about 8%. Penile hematoma and ecchymosis occurred in 3 and 2% of patients, respectively; most cases were attributed to improper administration technique. The manufacturers' labeling should be consulted for other less common adverse effects associated with intracavernosal alprostadil and for additional information on usual precautions associated with such therapy.
Intraurethral alprostadil therapy (in the home setting) should be administered at the dose that was determined as optimal during titration in a medical setting; no more than 2 urethral suppositories should be used within a 24-hour period. Erection that lasts longer than desired may be relieved by the application of an ice pack alternately to each inner thigh for a period not exceeding 10 minutes.
Prolonged erection (persisting 4-6 hours) or priapism (erection persisting 6 hours or longer) occurred in 0.3 and less than 0.1% of patients, respectively, receiving intarurethral alprostadil in clinical studies.
Since priapism is a medical emergency that could result in penile tissue damage and permanent loss of potency if not treated immediately, patients should be advised to report promptly to their clinician or, if their clinician is unavailable, to seek alternative immediate medical attention if an erection occurs that persists longer than 4-6 hours or is extremely painful. The manufacturer of alprostadil urethral suppositories states that in patients who develop priapism or prolonged erection, dose should be decreased or, alternatively, discontinuance of intraurethral alprostadil therapy should be considered.
The most common adverse effect associated with intraurethral alprostadil is penile, urethral, or testicular pain, which was reported in 36, 13, or 5% of patients, respectively. In most cases, such pain was described as mild and transient, although about 7% of patients discontinued therapy with the drug because of such pain. Urethral bleeding and/or spotting and other minor urethral abrasions were reported in about 3% of patients.
Adverse effects associated with intraurethral alprostadil that were reported in sexual partners included vaginal burning and/or itching; however, a causal relationship to the drug has not been established and it is not known if these effects were associated with resumption of sexual intercourse. Dizziness, symptomatic hypotension, or syncope was reported in 4, 3, or 0.4% of patients, respectively, using alprostadil urethral suppositories during the intial (dose-titrating) phase.
Patients should be warned to avoid tasks requiring physical coordination (e.g., operating machinery, driving a motor vehicle) that could result in injury if hypotension or syncope were to occur following the use of such suppositories. In addition, patients should be advised to lie down and immediately raise their legs if they experience a light-headed feeling, dizziness, feeling of faintness, or rapid pulse and to promptly contact their clinician if symptoms persist.
If a response is observed, at least 24 hours should elapse before administering the next dose. Dosage should be titrated slowly to the lowest possible effective level in order to avoid priapism.
For the treatment of neurogenic impotence secondary to spinal cord injury, the usual adult intracavernosal dose of alprostadil ranges from 1.25-60 mcg. Generally, therapy is started with the smaller dosage and increased until the optimum dose (as determined by maintenance of an erection that is satisfactory for intercourse but persists no longer than 1 hour) is attained.
For the treatment of pure neurogenic impotence (i.e., spinal cord injury), the manufacturers recommend an initial intracavernosal dose of 1.25 mcg of alprostadil administered in a medical setting. If no response is observed with the initial dose of alprostadil, the dose may be doubled to 2.5
mcg after about 1 hour; no more than 2 doses should be administered within a 24-hour period. If additional dosage titration is required, a dose of 5 mcg may be administered during the next 24 hours, followed by subsequent increases in 5-mcg increments, with each incremental increase separated by at least 24 hours, until optimum response is achieved. If the duration of the erection achieved exceeds 1 hour, the subsequent dose of alprostadil should be reduced.
For the treatment of vasculogenic erectile dysfunction, psychogenic erectile dysfunction, or erectile dysfunction of mixed etiology, the manufacturers recommend an initial intracavernosal test dose of alprostadil of 2.5 mcg. If a partial response is observed, the dose may be doubled to 5 mcg after about 1 hour.
If no response to the initial test dose is observed, then the second dose may be increased to 7.5 mcg after about 1 hour. No more than 2 doses should be administered within a 24-hour period.
If additional titration is required, dosage may be increased in increments of 5-10 mcg at intervals of at least 24 hours until optimum response is achieved.
In clinical trials, most patients with erectile dysfunction of various etiologies responded to initial intracavernosal alprostadil doses titrated to exceeding 5 but not exceeding 20 mcg, with the dose at the end of the titration phase averaging 17.8 mcg. Although doses ranging from 0.2-140
mcg have been reported, almost all patients who respond to alprostadil do so at doses of 60 mcg or less; therefore, doses exceeding 60-65 mcg generally are not recommended.
Dosage of intraurethral alprostadil should be individualized according to the patient's erectile response. Since symptomatic hypotension and syncope occurred in 3 and 0.4% of patients, respectively, using intraurethral alprostadil during the initial (dose-titrating) phase, initiation and titration of dosage should be undertaken in a medical setting to monitor the patients for manifestations of such effects.
Patients should inform their clinician if they have a history of syncope. It is recommended that therapy with intraurethral alprostadil be initiated with low doses (e.g., 125 or 250 mcg); dosage should be titrated (in separate visits) to the lowest possible effective level in order to avoid development of hypotension or syncope, which appear to be dose related. If no response occurs with these doses, subsequent doses may be increased in a stepwise manner to 500 or 1000 mcg, as needed.
In clinical studies, 6-10, 17-20, 20-30 or 27-56% of patients achieved adequate penile response (erections sufficient for intercourse) at intraurethral alprostadil doses during the dosage-titration phase (to establish home maintenance dosage) of 125-, 250-, 500-, or 1000 mcg, respectively.
Intracavernosal alprostadil self-injection therapy for erectile dysfunction should be initiated at the dose that was determined as optimal during titration in a medical setting (e.g., physician's office); however, the first self-administered dose should be delayed for at least 1 day after completion of supervised dose titration but also should be administered in a medical setting. The optimal maintenance dose should result in an erection that is maintained for no longer than 1 hour. Adjustments to the initial office-titrated dose often are required to maintain response in the home, but should be attempted only after consultation with a clinician (not independently by the patient), following the same initial titration guidelines.
The manufacturers recommend that patients self-administer intracavernosal alprostadil no more frequently than 3 times weekly with at least 1 day elapsing between each dose. Follow-up monitoring of patients should be performed every 3 months to determine safety (e.g., careful examination of the penis for fibrotic changes) and the possible need for additional dosage adjustment. Alprostadil therapy should be discontinued if penile angulation, cavernosal fibrosis, or Peyronie's disease develop.
The manufacturer of Caverject(R) states that efficacy of long-term alprostadil therapy for erectile dysfunction has been established for up to 6 months by an uncontrolled, self-injection study; at 6 months, the optimal dose averaged 20.7 mcg. Doses exceeding 60-65 mcg generally are not recommended.
Prolonged erection (persisting 4-6 hours) or priapism (erection persisting 6 hours or longer) occurred in 4 or 0.4% of patients, respectively, receiving intracavernosal alprostadil in clinical studies. However, priapism is a medical emergency that could result in penile tissue damage and permanent loss of potency if not treated immediately, and therefore, patients should be advised to report promptly to their physician or, if unavailable, to seek alternative immediate medical attention if an erection that persists longer than 4 hours or that is extremely painful occurs.
Management of priapism or prolonged erection should be according to established medical practice, and has included aspiration of cavernosal blood and/or intracavernosal injection of an alpha-adrenergic agonist (i.e., phenylephrine, epinephrine) or dopamine; priapism may be more likely during dose titration than during maintenance (home) therapy. Rarely, more radical therapy for priapism (e.g., cavernospongiosus or Winter's shunt) may be necessary, such as in patients with persistent priapism (e.g., for longer than 24 hours).
The most common adverse effect associated with intracavernosal alprostadil use is penile pain, which was reported at least once in 37% of patients in clinical studies of up to 18 months' duration. In most cases, such pain was described as mild to moderate in intensity, although 3% of patients discontinued therapy with the drug because of penile pain. Patients should be advised to report to their clinician penile pain that develops or intensifies during intracavernosal alprostadil therapy.
Patients also should be vigilant for the development of nodules or hard areas in the penis and be instructed to report any sign of infection (e.g., penile erythema, swelling, tenderness, or unusual curvature).
Penile fibrosis, including Peyronie's disease, developed in 3% of patients receiving intracavernosal alprostadil in clinical studies; in one self-injection study in which the drug was administered for up to 18 months, the incidence of fibrosis was about 8%. Penile hematoma and ecchymosis occurred in 3 and 2% of patients, respectively; most cases were attributed to improper administration technique. The manufacturers' labeling should be consulted for other less common adverse effects associated with intracavernosal alprostadil and for additional information on usual precautions associated with such therapy.
Intraurethral alprostadil therapy (in the home setting) should be administered at the dose that was determined as optimal during titration in a medical setting; no more than 2 urethral suppositories should be used within a 24-hour period. Erection that lasts longer than desired may be relieved by the application of an ice pack alternately to each inner thigh for a period not exceeding 10 minutes.
Prolonged erection (persisting 4-6 hours) or priapism (erection persisting 6 hours or longer) occurred in 0.3 and less than 0.1% of patients, respectively, receiving intarurethral alprostadil in clinical studies.
Since priapism is a medical emergency that could result in penile tissue damage and permanent loss of potency if not treated immediately, patients should be advised to report promptly to their clinician or, if their clinician is unavailable, to seek alternative immediate medical attention if an erection occurs that persists longer than 4-6 hours or is extremely painful. The manufacturer of alprostadil urethral suppositories states that in patients who develop priapism or prolonged erection, dose should be decreased or, alternatively, discontinuance of intraurethral alprostadil therapy should be considered.
The most common adverse effect associated with intraurethral alprostadil is penile, urethral, or testicular pain, which was reported in 36, 13, or 5% of patients, respectively. In most cases, such pain was described as mild and transient, although about 7% of patients discontinued therapy with the drug because of such pain. Urethral bleeding and/or spotting and other minor urethral abrasions were reported in about 3% of patients.
Adverse effects associated with intraurethral alprostadil that were reported in sexual partners included vaginal burning and/or itching; however, a causal relationship to the drug has not been established and it is not known if these effects were associated with resumption of sexual intercourse. Dizziness, symptomatic hypotension, or syncope was reported in 4, 3, or 0.4% of patients, respectively, using alprostadil urethral suppositories during the intial (dose-titrating) phase.
Patients should be warned to avoid tasks requiring physical coordination (e.g., operating machinery, driving a motor vehicle) that could result in injury if hypotension or syncope were to occur following the use of such suppositories. In addition, patients should be advised to lie down and immediately raise their legs if they experience a light-headed feeling, dizziness, feeling of faintness, or rapid pulse and to promptly contact their clinician if symptoms persist.
Alprostadil is administered by intracavernosal injection for the treatment and diagnosis of erectile dysfunction, by urethral suppository for the treatment of erectile dysfunction, or by continuous IV or intra-arterial infusion to maintain the patency of the ductus arteriosus in neonates.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for PROSTIN VR PEDIATRIC (alprostadil):
There are 0 contraindications.
There are 1 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Alprostadil/Acetaminophen; NSAIDs SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Alprostadil is a prostaglandin E1 product used to maintain patency of a patent ductus arteriosus (PDA).(1) Acetaminophen and nonsteroidal anti-inflammatory (NSAID) agents inhibit prostaglandins and may be used for PDA closure in addition to pain/fever management.(2-4) CLINICAL EFFECTS: Simultaneous administration of acetaminophen or NSAIDs may result in decreased clinical effects from alprostadil, including reduction in PDA.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Avoid concurrent administration of acetaminophen or NSAIDs in patients on alprostadil for maintaining patency of a patent ductus arteriosus (PDA).(1) DISCUSSION: NSAIDs and acetaminophen are used as management for patent ductus arteriosus (PDA) closure.(2-4) Alprostadil is used to maintain patency of a PDA.(1) In a case report, a 37-week gestational age neonate with cardiac defects required alprostadil therapy for PDA patency. After multiple doses of acetaminophen for pain, an echocardiogram showed reduction of the PDA requiring increased doses of alprostadil. Additional acetaminophen was discontinued. Follow up echocardiogram showed successful reversal of PDA reduction and alprostadil dose was reduced.(5) |
ACETAMIN-CAFF-DIHYDROCODEINE, ACETAMINOPHEN, ACETAMINOPHEN-CODEINE, ANAPROX DS, ANJESO, APADAZ, ARTHROTEC 50, ARTHROTEC 75, BENZHYDROCODONE-ACETAMINOPHEN, BROMFENAC SODIUM, BUPIVACAINE-KETOROLAC-KETAMINE, BUTALB-ACETAMINOPH-CAFF-CODEIN, BUTALBITAL-ACETAMINOPHEN, BUTALBITAL-ACETAMINOPHEN-CAFFE, CALDOLOR, CELEBREX, CELECOXIB, COMBOGESIC, COMBOGESIC IV, CONSENSI, COXANTO, DAYPRO, DICLOFENAC, DICLOFENAC POTASSIUM, DICLOFENAC SODIUM, DICLOFENAC SODIUM ER, DICLOFENAC SODIUM MICRONIZED, DICLOFENAC SODIUM-MISOPROSTOL, DIFLUNISAL, DOLOBID, EC-NAPROSYN, ELYXYB, ENDOCET, ETODOLAC, ETODOLAC ER, FELDENE, FENOPROFEN CALCIUM, FENOPRON, FIORICET, FIORICET WITH CODEINE, FLURBIPROFEN, HYDROCODONE-ACETAMINOPHEN, HYDROCODONE-IBUPROFEN, IBU, IBUPAK, IBUPROFEN, IBUPROFEN LYSINE, IBUPROFEN-FAMOTIDINE, INDOCIN, INDOMETHACIN, INDOMETHACIN ER, INFLAMMACIN, INFLATHERM(DICLOFENAC-MENTHOL), KETOPROFEN, KETOPROFEN MICRONIZED, KETOROLAC TROMETHAMINE, KIPROFEN, LODINE, LOFENA, MECLOFENAMATE SODIUM, MEFENAMIC ACID, MELOXICAM, NABUMETONE, NABUMETONE MICRONIZED, NALFON, NALOCET, NAPRELAN, NAPROSYN, NAPROTIN, NAPROXEN, NAPROXEN SODIUM, NAPROXEN SODIUM CR, NAPROXEN SODIUM ER, NAPROXEN-ESOMEPRAZOLE MAG, NEOPROFEN, OXAPROZIN, OXYCODONE-ACETAMINOPHEN, PERCOCET, PHENYLBUTAZONE, PIROXICAM, PRIMLEV, PROLATE, R.E.C.K.(ROPIV-EPI-CLON-KETOR), RELAFEN DS, ROPIVACAINE-CLONIDINE-KETOROLC, ROPIVACAINE-KETOROLAC-KETAMINE, SPRIX, SULINDAC, SUMATRIPTAN SUCC-NAPROXEN SOD, SYMBRAVO, TENCON, TOLECTIN 600, TOLMETIN SODIUM, TORONOVA II SUIK, TORONOVA SUIK, TOXICOLOGY SALIVA COLLECTION, TRAMADOL HCL-ACETAMINOPHEN, TRESNI, TREXIMET, TREZIX, VIMOVO, VIVLODEX, XIFYRM, ZIPSOR, ZORVOLEX, ZYNRELEF |
There are 0 moderate interactions.
The following contraindication information is available for PROSTIN VR PEDIATRIC (alprostadil):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 1 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Pregnancy |
There are 3 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Apnea |
| Pyloroduodenal obstruction |
| Respiratory distress syndrome in the newborn |
There are 2 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Hypotension |
| Increased risk of bleeding |
The following adverse reaction information is available for PROSTIN VR PEDIATRIC (alprostadil):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 35 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Apnea |
Bradycardia Hypotension Seizure disorder Sepsis Tachycardia |
| Rare/Very Rare |
|---|
|
Anemia Anuria Bradypnea Cardiac arrest Chronic heart failure Disseminated intravascular coagulation Edema Erythema Hematuria Hemorrhage Hypercapnia Hyperkalemia Hypoglycemic disorder Hypokalemia Hypothermia Infantile cortical hyperostosis Intracerebral hemorrhage Lethargy Neck hyperextension Paroxysmal supraventricular tachycardia Peritonitis Respiratory depression Respiratory distress syndrome in the newborn Second degree atrioventricular heart block Shock Tachypnea Thrombocytopenic disorder Ventricular fibrillation Wheezing |
There are 6 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Fever Flushing |
Diarrhea |
| Rare/Very Rare |
|---|
|
Irritability Muscle rigidity Vomiting |
The following precautions are available for PROSTIN VR PEDIATRIC (alprostadil):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for PROSTIN VR PEDIATRIC (alprostadil):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for PROSTIN VR PEDIATRIC (alprostadil)'s list of indications:
| Congenital defect requiring patency of ductus arteriosus | |
| Q20.3 | Discordant ventriculoarterial connection |
| Q21.3 | Tetralogy of fallot |
| Q22.0 | Pulmonary valve atresia |
| Q22.1 | Congenital pulmonary valve stenosis |
| Q22.4 | Congenital tricuspid stenosis |
| Q22.9 | Congenital malformation of tricuspid valve, unspecified |
| Q25.1 | Coarctation of aorta |
| Q25.4 | Other congenital malformations of aorta |
| Q25.5 | Atresia of pulmonary artery |
Formulary Reference Tool